Canaccord Genuity analyst Kyle Rose maintained a Buy rating on SI-Bone (NASDAQ:SIBN) Inc on Monday, setting a price target of $40, which is approximately 11.23% above the present share price of $35.96.
Rose expects SI-Bone Inc to post earnings per share (EPS) of -$0.28 for the second quarter of 2021.
The current consensus among 4 TipRanks analysts is for a Strong Buy rating of shares in SI-Bone, with an average price target of $38.25.
The analysts price targets range from a high of $42 to a low of $35.
In its latest earnings report, released on 12/31/2020, the company reported a quarterly revenue of $22.14 million and a net profit of -$7.87 million. The company's market cap is $1.18 billion.
According to TipRanks.com, Canaccord Genuity analyst Kyle Rose is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 19.6% and a 60.17% success rate.
SI-BONE, Inc. is a medical device company, which engages in the research and development of minimally invasive surgical implant system. Its product, iFuse, seeks to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that often causes severe lower back pain. The company was founded by Mark A. Reiley and Jeffrey W. Dunn on March 18, 2008 and is headquartered in San Jose, CA.